A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Song, Ying Chyi ^a,b   Liu, Shih Jen ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9; VACCINE;

AGONISTS; CPG ISLAND; HUMAN; IMMUNOLOGY;

CPG ISLANDS; HUMANS; PEPTIDES; TOLL-LIKE RECEPTOR 9; VACCINES;

EID: 84938226194     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12578     Document Type: Article

References (55)

1. Berzofsky, J. A. et al. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 170, 151-172 (1999).
2. Lechmann, M. & Liang, T. J. Vaccine development for hepatitis C. Semin Liver Dis 20, 211-226, doi: 10.1055/s-2000-9947 (2000).
3. Paul, W. E. Can the immune response control HIV infection? Cell 82, 177-182 (1995).
4. BenMohamed, L., Wechsler, S. L. & Nesburn, A. B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2, 425-431 (2002).
5. Hans, D., Young, P. R. & Fairlie, D. P. Current status of short synthetic peptides as vaccines. Med Chem 2, 627-646 (2006).
6. Song, Y. C. et al. Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo. J Leukoc Biol 90, 323-332 (2011).
7. Vogel, F. R. & Powell, M. F. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 6, 141-228 (1995).
8. Gupta, R. K., Rost, B. E., Relyveld, E. & Siber, G. R. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol 6, 229-248 (1995).
9. Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4, 249-258 (2004).
10. Klinman, D. M., Xie, H., Little, S. F., Currie, D. & Ivins, B. E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22, 2881-2886 (2004).
11. McCluskie, M. J. & Krieg, A. M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 311, 155-178 (2006).
12. Cooper, C. L. et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24, 693-701, doi: 10.1007/s10875-004-6244-3 (2004).
13. Halperin, S. A. et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21, 2461-2467 (2003).
14. Brazolot Millan, C. L., Weeratna, R., Krieg, A. M., Siegrist, C. A. & Davis, H. L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 95, 15553-15558 (1998).
15. Wooldridge, J. E., Ballas, Z., Krieg, A. M. & Weiner, G. J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89, 2994-2998 (1997).
16. Zhu, Q. et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 120, 607-616 (2010).
17. Krishnamachari, Y. & Salem, A. K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 61, 205-217 (2009).
18. Mutwiri, G. K., Nichani, A. K., Babiuk, S. & Babiuk, L. A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release 97, 1-17 (2004).
19. Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
20. Daftarian, P. et al. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 23, 3453-3468 (2005).
21. Muraoka, D. et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol 185, 3768-3776 (2010).
22. Sparwasser, T. et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28, 2045-2054 (1998).
23. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C. & Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20, 621-667 (2002).
24. Xiang, S. D. et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40, 1-9 (2006).
25. Dresch, C., Leverrier, Y., Marvel, J. & Shortman, K. Development of antigen cross-presentation capacity in dendritic cells. Trends Immunol 33, 381-388 (2012).
26. Aichinger, M. C. et al. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine 29, 426-436 (2011).
27. Chuang, C. M., Monie, A., Wu, A., Mao, C. P. & Hung, C. F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 20, 303-313, doi: 10.1089/hum.2008.124 (2009).
28. Steinman, R. M. & Swanson, J. The endocytic activity of dendritic cells. J Exp Med 182, 283-288 (1995).
29. Ahmad-Nejad, P. et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32, 1958-1968 (2002).
30. Lahoud, M. H. et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci USA 109, 16270-16275 (2012).
31. Park, B. et al. Granulin is a soluble cofactor for toll-like receptor 9 signaling. Immunity 34, 505-513 (2011).
32. Huang, A. Y. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965 (1994).
33. Sigal, L. J., Crotty, S., Andino, R. & Rock, K. L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398, 77-80, doi: 10.1038/18038 (1999).
34. Datta, S. K. et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 170, 4102-4110 (2003).
35. Maurer, T. et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 32, 2356-2364 (2002).
36. Rudd, B. D., Brien, J. D., Davenport, M. P. & Nikolich-Zugich, J. Cutting edge: TLR ligands increase TCR triggering by slowing peptide-MHC class I decay rates. J Immunol 181, 5199-5203 (2008).
37. Jiang, W., Lederman, M. M., Harding, C. V. & Sieg, S. F. Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells. J Immunol 186, 2080-2086 (2011).
38. Kiura, K. et al. The synthetic analogue of mycoplasmal lipoprotein FSL-1 induces dendritic cell maturation through Toll-like receptor 2. FEMS Immunol Med Microbiol 46, 78-84 (2006).
39. Shen, K. Y. et al. Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol 192, 4233-4241 (2014).
40. Gil-Torregrosa, B. C. et al. Control of cross-presentation during dendritic cell maturation. Eur J Immunol 34, 398-407, doi: 10.1002/eji.200324508 (2004).
41. Pulendran, B. et al. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 167, 5067-5076 (2001).
42. Schulz, O. et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433, 887-892 (2005).
43. Bourquin, C. et al. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood 109, 2953-2960 (2007).
44. Crespo, M. I. et al. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8alpha+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface. J Immunol 190, 948-960 (2013).
45. Mouries, J. et al. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112, 3713-3722 (2008).
46. Latz, E. et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5, 190-198 (2004).
47. Moseman, A. P. et al. Mannose receptor 1 mediates cellular uptake and endosomal delivery of CpG-motif containing oligodeoxynucleotides. J Immunol 191, 5615-5624 (2013).
48. Guiducci, C. et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 203, 1999-2008 (2006).
49. Di Pucchio, T. et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 9, 551-557 (2008).
50. Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307, 1630-1634 (2005).
51. Shen, L., Sigal, L. J., Boes, M. & Rock, K. L. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21, 155-165 (2004).
52. Burgdorf, S., Scholz, C., Kautz, A., Tampe, R. & Kurts, C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9, 558-566 (2008).
53. Spadaro, F. et al. IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119, 1407-1417 (2012).
54. Chen, H. W. et al. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 27, 1400-1409 (2009).
55. Busetto, S., Trevisan, E., Patriarca, P. & Menegazzi, R. A single-step, sensitive flow cytofluorometric assay for the simultaneous assessment of membrane-bound and ingested Candida albicans in phagocytosing neutrophils. Cytometry A 58, 201-206, doi: 10.1002/cyto.a.20014 (2004).